Cargando…
How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers
To evaluate China's current rifampin-resistant tuberculosis (RR-TB) screening strategy from stakeholders' perspectives, the perceptions, attitudes, and interests of 245 stakeholders from three eastern, central, and western China provinces on RR-TB screening strategies, were investigated th...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651999/ https://www.ncbi.nlm.nih.gov/pubmed/34900894 http://dx.doi.org/10.3389/fpubh.2021.736632 |
_version_ | 1784611497313304576 |
---|---|
author | Hua, Qianhui Xu, Hong Chen, Xinyi Pan, Junhang Peng, Ying Wang, Wei Chen, Bin Jiang, Jianmin |
author_facet | Hua, Qianhui Xu, Hong Chen, Xinyi Pan, Junhang Peng, Ying Wang, Wei Chen, Bin Jiang, Jianmin |
author_sort | Hua, Qianhui |
collection | PubMed |
description | To evaluate China's current rifampin-resistant tuberculosis (RR-TB) screening strategy from stakeholders' perspectives, the perceptions, attitudes, and interests of 245 stakeholders from three eastern, central, and western China provinces on RR-TB screening strategies, were investigated through stakeholder survey and interview. The attitudes toward three RR-TB screening strategies were statistically different: inclination to choose who to screen (Z = 98.477; P < 0.001), funding for rapid diagnostic technology screening either by reimbursed health insurance or directly subsidized financial assistance (Z = 4.142, P < 0.001), and respondents' attitude during RR-TB screening implementation levels (Z = 2.380, P = 0.017). In conclusion, RR-TB screening scope could be expanded by applying rapid diagnostic technologies. Provinces with different economic status could adjust their screening policies accordingly. |
format | Online Article Text |
id | pubmed-8651999 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86519992021-12-09 How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers Hua, Qianhui Xu, Hong Chen, Xinyi Pan, Junhang Peng, Ying Wang, Wei Chen, Bin Jiang, Jianmin Front Public Health Public Health To evaluate China's current rifampin-resistant tuberculosis (RR-TB) screening strategy from stakeholders' perspectives, the perceptions, attitudes, and interests of 245 stakeholders from three eastern, central, and western China provinces on RR-TB screening strategies, were investigated through stakeholder survey and interview. The attitudes toward three RR-TB screening strategies were statistically different: inclination to choose who to screen (Z = 98.477; P < 0.001), funding for rapid diagnostic technology screening either by reimbursed health insurance or directly subsidized financial assistance (Z = 4.142, P < 0.001), and respondents' attitude during RR-TB screening implementation levels (Z = 2.380, P = 0.017). In conclusion, RR-TB screening scope could be expanded by applying rapid diagnostic technologies. Provinces with different economic status could adjust their screening policies accordingly. Frontiers Media S.A. 2021-11-24 /pmc/articles/PMC8651999/ /pubmed/34900894 http://dx.doi.org/10.3389/fpubh.2021.736632 Text en Copyright © 2021 Hua, Xu, Chen, Pan, Peng, Wang, Chen and Jiang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Public Health Hua, Qianhui Xu, Hong Chen, Xinyi Pan, Junhang Peng, Ying Wang, Wei Chen, Bin Jiang, Jianmin How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers |
title | How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers |
title_full | How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers |
title_fullStr | How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers |
title_full_unstemmed | How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers |
title_short | How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers |
title_sort | how to effectively identify patients with rifampin-resistant tuberculosis in china: perspectives of stakeholders among service providers |
topic | Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651999/ https://www.ncbi.nlm.nih.gov/pubmed/34900894 http://dx.doi.org/10.3389/fpubh.2021.736632 |
work_keys_str_mv | AT huaqianhui howtoeffectivelyidentifypatientswithrifampinresistanttuberculosisinchinaperspectivesofstakeholdersamongserviceproviders AT xuhong howtoeffectivelyidentifypatientswithrifampinresistanttuberculosisinchinaperspectivesofstakeholdersamongserviceproviders AT chenxinyi howtoeffectivelyidentifypatientswithrifampinresistanttuberculosisinchinaperspectivesofstakeholdersamongserviceproviders AT panjunhang howtoeffectivelyidentifypatientswithrifampinresistanttuberculosisinchinaperspectivesofstakeholdersamongserviceproviders AT pengying howtoeffectivelyidentifypatientswithrifampinresistanttuberculosisinchinaperspectivesofstakeholdersamongserviceproviders AT wangwei howtoeffectivelyidentifypatientswithrifampinresistanttuberculosisinchinaperspectivesofstakeholdersamongserviceproviders AT chenbin howtoeffectivelyidentifypatientswithrifampinresistanttuberculosisinchinaperspectivesofstakeholdersamongserviceproviders AT jiangjianmin howtoeffectivelyidentifypatientswithrifampinresistanttuberculosisinchinaperspectivesofstakeholdersamongserviceproviders |